This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shi, J. Articles by Mitchison, T. Search for Related Content PubMed PubMed Citation Articles by Shi, J. Articles by Mitchison, T.

Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5

Department of Systems Biology, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Jue Shi, Harvard Medical School, Room 541, Warren Alpert, 200 Longwood Avenue, Boston, MA 02115. Phone: 617-432-3724; Fax: 617-432-5012; E-mail: jue_shi{at}hms.harvard.edu.

Key Words: antimitotics • cell type variation • drug response

To improve cancer chemotherapy, we need to understand the mechanisms that determine drug sensitivity in cancer and normal cells. Here, we investigate this question across a panel of 11 cell lines at a phenotypic and molecular level for three antimitotic drugs: paclitaxel, nocodazole, and an inhibitor of kinesin-5 (also known as KSP, Eg5, Kif11). Using automated microscopy with markers for mitosis and apoptosis (high content screening), we find that the mitotic arrest response shows relatively little variation between cell types, whereas the tendency to undergo apoptosis shows large variation. We found no correlation between levels of mitotic arrest and apoptosis. Apoptosis depended on entry into mitosis and occurred both from within mitosis and after exit. Response to the three drugs strongly correlated, although paclitaxel caused more apoptosis in some cell lines at similar levels of mitotic arrest. Molecular investigations showed that sensitivity to apoptosis correlated with loss of an antiapoptotic protein, XIAP, during the drug response, but not its preresponse levels, and to some extent also correlated with activation of the p38 and c-Jun NH₂ kinase pathways. We conclude that variation in sensitivity to antimitotic drugs in drug-naive cell lines is governed more by differences in apoptotic signaling than by differences in mitotic spindle or spindle assembly checkpoint proteins and that antimitotics with different mechanisms trigger very similar, but not identical, responses. [Cancer Res 2008;68(9):3269–76]

This article has been cited by other articles:

				Z. Yang, A. E. Kenny, D. A. Brito, and C. L. Rieder Cells satisfy the mitotic checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic attachments J. Cell Biol., September 7, 2009; 186(5): 675 - 684. [Abstract] [Full Text] [PDF]

				K. E. Gascoigne and S. S. Taylor How do anti-mitotic drugs kill cancer cells? J. Cell Sci., August 1, 2009; 122(15): 2579 - 2585. [Abstract] [Full Text] [PDF]

				M. E. Bekier, R. Fischbach, J. Lee, and W. R. Taylor Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit Mol. Cancer Ther., June 1, 2009; 8(6): 1646 - 1654. [Abstract] [Full Text] [PDF]

				C. Swanton, B. Nicke, M. Schuett, A. C. Eklund, C. Ng, Q. Li, T. Hardcastle, A. Lee, R. Roy, P. East, et al. Chromosomal instability determines taxane response PNAS, May 26, 2009; 106(21): 8671 - 8676. [Abstract] [Full Text] [PDF]

				J. D. Orth, Y. Tang, J. Shi, C. T. Loy, C. Amendt, C. Wilm, F. T. Zenke, and T. J. Mitchison Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate Mol. Cancer Ther., November 1, 2008; 7(11): 3480 - 3489. [Abstract] [Full Text] [PDF]